IMCR - Immunocore Holdings Ltd

https://www.immunocore.com

Momentum: Bearish

Recent News

Immunocore ( IMCR ) Q2 Revenue Jumps 30%

Motley Fool • 1 month, 1 week ago • score: 0.07

Immunocore Plc ( NASDAQ:IMCR ) , a biotechnology company specializing in T cell receptor therapies, reported its second quarter 2025 results on August 7, 2025. The main headline was a solid revenue increase, with $98.0 million ( GAAP ) surpassing consensus estimates of $92.15 million.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.

52W High

$39.33

52W Low

$23.15

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.77

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-45.82

EV/Revenue (<3 favorable)

4.01

P/S (TTM) (<3 favorable)

5.26

P/B (<3 favorable)

4.83

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

5.08%

Institutions (25–75% balanced)

98.21%

Shares Outstanding

50,387,000

Float

37,572,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

356,145,000

Gross Profit (TTM)

328,780,000

EPS (TTM)

-0.41

Profit Margin (>10% good)

-0.06%

Operating Margin (TTM) (higher better)

-0.15%

ROE (TTM) (>15% strong)

-0.05%

EPS YoY (Quarterly) (>10% good)

8.22

Revenue YoY (Quarterly) (>8% good)

0.30

Momentum

Bearish momentum

Value

1.0515

1.1588

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025